The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) ...

Mr. Sarcevic will serve on the Company’s Audit Committee and its Compensation Committee.

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

A 3,500-square-foot Starbucks has opened on the site that was once home to pharmaceutical giant Hoffmann-La Roche in Clifton.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

Shares of Disc Medicine Inc. (NASDAQ:IRON) were trading at $56.94, up $9.81, or 20%, after the firm disclosed positive feedback from its end-of-phase II meeting with the FDA, supporting the regulatory ...

An Alzheimer's drug that had been hailed as a major breakthrough may actually increase patients' chance of dying, according ...

Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.